You are here

  • Home
  • Archive
  • Volume 12, Issue 5
  • Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Citation Tools

Article menu
Immune cell therapies and immune cell engineering
Original research
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gargett T, Truong NTH, Gardam B, et al
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers
Journal for ImmunoTherapy of Cancer 2024;12:e008659. doi: 10.1136/jitc-2023-008659